Alexander Belcredi serves as the CEO of PhagoMed Biopharma GmbH, a company he co-founded in 2017. Before setting up the company, Alexander spent close to 10 years at The Boston Consulting Group (BCG). In his last role as Principal he advised multinational pharmaceutical and medical technologies clients on a wide range of strategic topics and was a member of BCG’s Global Medical Technologies Leadership Team.
While at BCG, Alexander became acutely aware of the urgent need to develop alternatives to small-molecule antibiotics. Fascinated by the role that phage therapy can play as an antibiotics alternative, Alexander formed a small team centered around Prof. Wippermann and Dr. Corsini in early 2016 to review options for how to accelerate the re-introduction of phage therapy in Western medicine. In 2017 Alexander quit his job at BCG to co-found PhagoMed. Alexander holds an M.A. from St. Andrews University in Modern History and Economics as well as an MBA from INSEAD.